Shopping Cart
- Remove All
Your shopping cart is currently empty
Lp-PLA2-IN-3 is a potent, orally bioactive lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, effectively inhibiting recombinant human [Lp-PLA2] with an IC50 value of 14 nM.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $97 | In Stock | |
| 2 mg | $142 | In Stock | |
| 5 mg | $239 | In Stock | |
| 10 mg | $378 | In Stock | |
| 25 mg | $627 | In Stock | |
| 50 mg | $886 | In Stock | |
| 100 mg | $1,180 | In Stock | |
| 500 mg | $2,380 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $245 | In Stock |
| Description | Lp-PLA2-IN-3 is a potent, orally bioactive lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, effectively inhibiting recombinant human [Lp-PLA2] with an IC50 value of 14 nM. |
| Targets&IC50 | Lp-PLA2:14 nM |
| In vivo | Lp-PLA2-IN-3 (1 mg/kg; i.v.) treatment shows the CL, Vss, and t1/2 were 3.1mL/min/kg, 0.3 L/kg, 4 hours, respectively.[1] Lp-PLA2-IN-3 (3 mg/kg; p.o.) treatment shows the Cmax, AUC0-24h, t1/2, and F were 0.27 μg/mL, 3.4 μg h/mL, 7.7 hours, and 35.5%, respectively.[1] |
| Molecular Weight | 467.85 |
| Formula | C20H13ClF3N3O3S |
| Cas No. | 2196245-16-4 |
| Smiles | Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Oc2ccc(Cl)c(c2)C(F)(F)F)c(c1)C#N |
| Relative Density. | 1.57 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (534.36 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (10.69 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.